IRVING, Texas, November 7, 2019 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Brian J. Brille, Vice Chairman of the Company, will present at two upcoming investor healthcare conferences in New York City. Presentation details are as follows:
- Stifel 2019 Healthcare Conference
Wednesday, November 20, 2019, at 10:20 a.m. Eastern Time,
Lotte New York Palace Hotel, Winslow Room
- Canaccord Genuity Group 2019 Medical Technologies & Diagnostics Forum
Thursday, November 21, 2019, at 11:00 a.m. Eastern Time,
The Westin Grand Central, Ambassador Room
Mr. Brille will provide an overview of Caris’ business at the conferences and discuss recent corporate achievements that position the Company to further extend its leadership in precision medicine. He will also take questions from the audience following each presentation.
Investors attending either conference who would like to schedule a one-on-one meeting with Caris executives may do so by contacting their representatives at Stifel or Canaccord Genuity Group, respectively.
About Caris Life Sciences
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. The company’s suite of market-leading molecular profiling offerings assesses DNA, RNA and proteins to reveal a molecular blueprint that helps physicians and cancer patients make more precise and personalized treatment decisions.
Caris is also advancing precision medicine with Next Generation Profiling™ that combines its innovative service offerings, Caris Molecular Intelligence® and ADAPT Biotargeting System™, with its proprietary artificial intelligence analytics engine, DEAN™, to analyze the whole exome, whole transcriptome and complete cancer proteome. This information, coupled with mature clinical outcomes on thousands of patients, provides unmatched molecular solutions for patients, physicians, payers and biopharmaceutical organizations.
Whole transcriptome sequencing with MI Transcriptome provides the most comprehensive and unique RNA analysis available on the market and covers all 22,000 genes, with an average of 60 million reads per patient, to deliver extremely broad coverage and high resolution into the dynamic nature of the transcriptome. Assessing the whole transcriptome allows us to dig deeper into the RNA universe to uncover and detect fusions, splice variants, and expression changes that provide oncologists with more insight and actionable information when determining treatment plans for patients.
Caris Pharmatech, a pioneer of the original Just-In-Time research system with the largest research-ready oncology network is changing the paradigm from the traditional physician outreach model to a real-time approach where patient identification is completed at the lab and the physician is informed so that the patient can be enrolled days earlier, and remain in the local physician’s care, without having to travel to a large central trial site. This fundamentally redefines how pharmaceutical and biotechnology companies identify and rapidly enroll patients in precision oncology trials by combining Caris’ highest quality industry leading large-scale molecular profiling services with Pharmatech’s on-demand site activation and patient enrollment system.
Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets. To learn more, please visit www.CarisLifeSciences.com or follow us on Twitter (@CarisLS).
# # #
Media & Company Contact:
Vice President, Chief Communications Officer